FDA approves former Genmab drug - royalties to follow
![Jan van de Winkel, CEO of Genmab, can look forward to another source of earnings for the company. | Foto: Mik Eskestad / Jyllands-Posten / Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11892892.ece/ALTERNATES/schema-16_9/20130118-182641-pf-1920x1078we.jpg)
Genmab can look forward to earnings in the hundreds of millions of kroner from a medicine that was otherwise dead and buried treatment, as biotech company Horizon Therapeutics has managed to get the drug, teprotumumab, approved by the FDA.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.